J Allergy Clin Immunol:过敏原免疫治疗能够改善过敏性鼻炎患者的滤泡调节性T细胞缺陷

2019-03-16 AlexYang MedSci原创

滤泡调节性T(Tfr)细胞功能,尤其是在调节过敏性疾病的lgE产生方面所知甚少。最近,有研究人员调查了过敏性鼻炎(AR)患者的Tfr细胞的表型、功能和临床相关性情况。研究发现,Tfr细胞在扁桃体发生中心检测到,但是与非AR受试者相比,对屋尘螨过敏的AR患者的检出频率减少。与健康对照相比,AR患者血液中的循环Tfr细胞在表型和数量上与扁桃体Tfr细胞和循环Tfr细胞的减少相关,但是与总的Treg细胞

滤泡调节性T(Tfr)细胞功能,尤其是在调节过敏性疾病的lgE产生方面所知甚少。最近,有研究人员调查了过敏性鼻炎(AR)患者的Tfr细胞的表型、功能和临床相关性情况。

研究发现,Tfr细胞在扁桃体发生中心检测到,但是与非AR受试者相比,对屋尘螨过敏的AR患者的检出频率减少。与健康对照相比,AR患者血液中的循环Tfr细胞在表型和数量上与扁桃体Tfr细胞和循环Tfr细胞的减少相关,但是与总的Treg细胞或者CXCR5-Treg细胞没有关系。更多的是,AR患者中的循环Tfr细胞在抑制lgE产生方面有着特异性的缺陷,但是却能够抑制其他免疫球蛋白类型。另外,研究人员在AR患者中还检测到了Tfr细胞频率和功能与抗原特异性lgE或者疾病严重度呈现负相关关系。AIT之后,Tfr的频率和功能得到了改善,且与疾病的缓解相关。

最后,研究人员指出,Tfr细胞的损伤可能导致AR患者中lgE产生的异常,AIT能够改善Tfr细胞功能。Tfr细胞也许可以作为监测AIT临床响应的一种生物标记。

原始出处:

Yao Y, Wang ZC, Wang N et al. Allergen immunotherapy improves defective follicular regulatory T cells in patients with allergic rhinitis. J Allergy Clin Immunol. 20 Feb 2019.

本文系williamhill asia 医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047090, encodeId=55c0204e0904e, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 07 17:52:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366609, encodeId=b0b63666092f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed May 22 20:54:30 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364546, encodeId=0a273645460c, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Apr 12 17:35:24 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363435, encodeId=0383363435a7, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Mar 23 19:39:51 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329219, encodeId=fe7113292199d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442624, encodeId=766f1442624c1, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362906, encodeId=047c36290699, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Mar 17 21:08:05 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362739, encodeId=4d1f362e39e7, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3392507337, createdName=124b08b0m75(暂无昵称), createdTime=Sat Mar 16 13:15:21 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047090, encodeId=55c0204e0904e, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 07 17:52:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366609, encodeId=b0b63666092f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed May 22 20:54:30 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364546, encodeId=0a273645460c, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Apr 12 17:35:24 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363435, encodeId=0383363435a7, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Mar 23 19:39:51 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329219, encodeId=fe7113292199d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442624, encodeId=766f1442624c1, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362906, encodeId=047c36290699, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Mar 17 21:08:05 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362739, encodeId=4d1f362e39e7, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3392507337, createdName=124b08b0m75(暂无昵称), createdTime=Sat Mar 16 13:15:21 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-05-22 wxl882001

    了解一下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2047090, encodeId=55c0204e0904e, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 07 17:52:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366609, encodeId=b0b63666092f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed May 22 20:54:30 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364546, encodeId=0a273645460c, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Apr 12 17:35:24 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363435, encodeId=0383363435a7, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Mar 23 19:39:51 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329219, encodeId=fe7113292199d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442624, encodeId=766f1442624c1, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362906, encodeId=047c36290699, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Mar 17 21:08:05 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362739, encodeId=4d1f362e39e7, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3392507337, createdName=124b08b0m75(暂无昵称), createdTime=Sat Mar 16 13:15:21 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-04-12 wxl882001

    了解一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2047090, encodeId=55c0204e0904e, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 07 17:52:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366609, encodeId=b0b63666092f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed May 22 20:54:30 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364546, encodeId=0a273645460c, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Apr 12 17:35:24 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363435, encodeId=0383363435a7, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Mar 23 19:39:51 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329219, encodeId=fe7113292199d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442624, encodeId=766f1442624c1, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362906, encodeId=047c36290699, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Mar 17 21:08:05 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362739, encodeId=4d1f362e39e7, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3392507337, createdName=124b08b0m75(暂无昵称), createdTime=Sat Mar 16 13:15:21 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-03-23 wxl882001

    了解一下

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2047090, encodeId=55c0204e0904e, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 07 17:52:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366609, encodeId=b0b63666092f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed May 22 20:54:30 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364546, encodeId=0a273645460c, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Apr 12 17:35:24 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363435, encodeId=0383363435a7, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Mar 23 19:39:51 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329219, encodeId=fe7113292199d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442624, encodeId=766f1442624c1, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362906, encodeId=047c36290699, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Mar 17 21:08:05 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362739, encodeId=4d1f362e39e7, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3392507337, createdName=124b08b0m75(暂无昵称), createdTime=Sat Mar 16 13:15:21 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-03-18 膀胱癌
  6. [GetPortalCommentsPageByObjectIdResponse(id=2047090, encodeId=55c0204e0904e, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 07 17:52:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366609, encodeId=b0b63666092f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed May 22 20:54:30 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364546, encodeId=0a273645460c, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Apr 12 17:35:24 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363435, encodeId=0383363435a7, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Mar 23 19:39:51 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329219, encodeId=fe7113292199d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442624, encodeId=766f1442624c1, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362906, encodeId=047c36290699, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Mar 17 21:08:05 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362739, encodeId=4d1f362e39e7, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3392507337, createdName=124b08b0m75(暂无昵称), createdTime=Sat Mar 16 13:15:21 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2047090, encodeId=55c0204e0904e, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 07 17:52:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366609, encodeId=b0b63666092f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed May 22 20:54:30 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364546, encodeId=0a273645460c, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Apr 12 17:35:24 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363435, encodeId=0383363435a7, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Mar 23 19:39:51 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329219, encodeId=fe7113292199d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442624, encodeId=766f1442624c1, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362906, encodeId=047c36290699, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Mar 17 21:08:05 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362739, encodeId=4d1f362e39e7, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3392507337, createdName=124b08b0m75(暂无昵称), createdTime=Sat Mar 16 13:15:21 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-03-17 医者仁心5538

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2047090, encodeId=55c0204e0904e, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Wed Aug 07 17:52:00 CST 2019, time=2019-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=366609, encodeId=b0b63666092f, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Wed May 22 20:54:30 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364546, encodeId=0a273645460c, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Apr 12 17:35:24 CST 2019, time=2019-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363435, encodeId=0383363435a7, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Sat Mar 23 19:39:51 CST 2019, time=2019-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329219, encodeId=fe7113292199d, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442624, encodeId=766f1442624c1, content=<a href='/topic/show?id=625194032a5' target=_blank style='color:#2F92EE;'>#过敏原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94032, encryptionId=625194032a5, topicName=过敏原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81884942400, createdName=12498cb5m14暂无昵称, createdTime=Mon Mar 18 03:52:00 CST 2019, time=2019-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362906, encodeId=047c36290699, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Mar 17 21:08:05 CST 2019, time=2019-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362739, encodeId=4d1f362e39e7, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b3392507337, createdName=124b08b0m75(暂无昵称), createdTime=Sat Mar 16 13:15:21 CST 2019, time=2019-03-16, status=1, ipAttribution=)]
    2019-03-16 124b08b0m75(暂无昵称)

    谢谢

    0

相关威廉亚洲官网

PLoS One:过敏性鼻炎儿科患者的急性鼻窦炎群体研究

虽然慢性鼻窦炎是过敏性鼻炎的常见并发症,而急性鼻窦炎与过敏性鼻炎之间的联系不清楚。最近,有研究人员利用基于群体的健康研究数据评估了患有过敏性鼻炎儿科患者的急性鼻窦炎发生率。研究包括了新诊断的年龄在5-18岁的过敏性鼻炎患者,并通过性别、年龄和年份指数匹配构建了一个比较群体。研究人员对所有的患者进行了跟踪调查,直到急性鼻窦炎诊断或者跟踪调查结束为止,并利用Cox比例风险模型评估了过敏性鼻炎和急性鼻窦

Clin Mol Allergy:过敏性鼻炎患者辅助疗法使用情况研究

辅助替代医学疗法(CAM)在欧洲以及意大利慢性疾病患者中的使用逐渐增加,其中包括了过敏性鼻炎疾病。最近,有研究人员调查了CAM在过敏性鼻炎患者中的流行度和使用模式。研究人员通过一个包括12个条目的调查问卷对中度到重度过敏性鼻炎患者进行调查,条目中覆盖了选择CAM的原因、临床效果、治疗计划、花费和治疗类型等。研究人员发现,分析的359分调查问卷中,20%的患者表明使用了CAM。研究发现,CAM的使用

Allergol Int:脂质体包裹的半乳糖酰基鞘氨醇舌下给药可以作为过敏性鼻炎的一种有效辅助过敏原免疫疗法

舌下免疫治疗(SLIT)是过敏性鼻炎(AR)治疗的有效方法。然而,SLIT需要长期的给药从而建立稳定和充分的响应。最近,有研究人员调查了舌下给药脂质体包裹的α-GalCer作为AR治疗的辅助治疗效果情况。研究人员将OVA诱导的AR小鼠分别接受OVA舌下给药、α-GC脂质体给药和OVA加α-GC脂质体给药3中不同的处理,为期7天。在进行OVA重复挑战之后,研究人员评估了鼻症状情况。另外,血清OVA特

Sci Rep:红洋葱提取物在过敏性鼻炎中局部给药治疗效果研究

最近,有研究人员评估了洋葱提取物鼻腔局部给药对过敏性鼻炎(AR)治疗的效果。研究人员将BALB/c小鼠通过腹腔内注射卵清蛋白(OVA)对小鼠进行敏化,并利用鼻内滴注OVA和OVA加洋葱提取物处理,连续进行3周,每周5次来进行处理。并根据打喷嚏、血清总免疫球蛋白E (IgE)水平、鼻粘膜细胞因子水平、嗜酸性粒细胞浸润对过敏性症状进行了分析。研究发现,过敏性症状评分、血清总和OVA诱导特异性lgE、鼻

Eur J Pharm Sci:色苷酸交联壳聚糖纳米粒子治疗过敏性鼻炎的效果研究

最近,有研究人员开发了粘膜粘着鼻血管收缩纳米粒子药物,具体是直接通过阳离子聚合物壳聚糖和阴离子药物色苷酸的交联来获得。研究人员利用不同的壳聚糖/色苷酸摩尔比来获得合适大小、包装效率/药物装载好和粘膜粘附能力好的纳米颗粒。更多的是,研究人员评估了纳米粒子传输色甘酸到鼻粘膜的能力。研究发现,获得的带正电纳米粒子且大小为180nm-400nm时,表现出让人感兴趣的产量、粘膜粘着能力和包装能力和药物装载能

Environ Sci Pollut Res Int:中国南京颗粒物质对过敏性鼻炎的影响研究

颗粒物质污染是一种严重的环境问题。接触颗粒物质的个体患病率增加。最近,有研究人员进行了流行病学研究来调查气体动力学直径小于10微米的颗粒物质(PM10)和小于2.5微米的颗粒物质(PM2.5)对中国南京过敏性鼻炎的影响。研究人员搜集了中国南京2014年1月到2016年12月的过敏性鼻炎患者日常数目(33063名患者)、PM10、PM2.5和天气数据,并利用广义加性模型(GAM)来评估PM10和PM